1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Europe Liver Cancer Market - Segmented by type, technology, end-user and geography (2015 - 2020)

Mordor Intelligence analysts forecasted the Europe Liver Cancer Market to grow at a CAGR of 7-15% over the period, 2015-2020. The market is currently valued at USD 176 million for the year 2015.

In the past 30 years there has been major progress in the knowledge and management of liver disease. Yet, approximately 29 million people in the European Union still suffer from one or the other chronic liver condition. Therefore, the liver cancer medication market is anticipated to become an active ground for competition in the near future. In Europe, 28% of the cases of liver cancer have been attributed to chronic HBV infection, and 21% to HCV infection. Other risk factors such as alcohol consumption, cigarette smoking and oral contraceptives may explain the residual variation within countries. Interactions among these risk factors have been postulated. New laboratory techniques and biological markers such as polymerase chain reaction detection of HBV DNA and HCV RNA, as well as specific mutations related to liver cancer, may help to provide quantitative estimates of the risks related to each these factors.

With only a few approved drugs within the market and another few in the pipeline, it is a proven fact that incidence and mortality from the sickness continues to rise worldwide. Many new-targeted therapies are expected to enter the market in the following few years. Targeted cancer therapies use medication to prevent the expansion of cancer cells by interrupting certain molecules, known as molecular targets, thereby preventing the progression and growth of cancer cells. The treatment, also known as 'molecular targeted therapy', focuses on the cellular and molecular changes, pertaining specifically to cancer. It is thereby more effective, as compared to the other treatments for cancer, including radiotherapy and chemotherapy..

The Europe liver cancer market is segmented based on:
- Type
o Primary
o Secondary
o Benign liver growths
- Diagnosis
- Ultrasound scans
- Confirmatory needle biopsy
- Endoscopic ultrasound
- Laparoscopy
- CT scan
- PET scan
- Magnetic resonance imaging (MRI) scans
- Therapeutics
- Hepatocellular carcinoma
- Cholangiocarcinoma
- Hepatoblastoma
- Targeted therapy
- Others
- End-User
- Pediatrics
- Adults

Some of the key participants in the industry include Bayer Schering Pharma AG, Onyx Pharmaceuticals, Inc., Celsion Corp., Alnylam Pharmaceuticals, Inc., ArQule, Inc., 4SC AG, ImClone Systems Inc., Jennerex Biotherapeutics, Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd., and Bristol-Myers Squibb Company. Etc.

- Increasing incidences of cancer
- Drug innovations with regard to the cancer
- Government initiatives
- Rise in aging populace
- Excessive alcohol consumptions
- High unmet needs for the treatment of liver cancer in the market
- Increasing health care expenditure

- Low success rate in clinical trials for cancer drugs
- Huge capital investments
- Low accessibility in remote areas
- Stringent regulatory procedures

Table Of Contents

Europe Liver Cancer Market - Segmented by type, technology, end-user and geography (2015 - 2020)
1. Executive Summary
2. Research Methodology
3. Introduction
3.1 Report Description
3.2 Markets Covered
4. Market Overview
4.1 Market Definition
4.2 Market Drivers
4.2.1 aging population
4.2.2 Rising Government and Non-Government Funding for Vaccine Development
4.2.3 high unmet needs for the treatment of liver cancer
4.2.4 excessive alcohol consumptions
4.3 Market Restraints
4.3.1 Techinical Advancements
4.3.2 Huge Capital Investments
4.3.3 Stringent Regulatory Procedures
4.3.4 Low success rate in clinical trails for cancer drugs
4.4 Market Opportunitites
4.5 Market Threats
5. Porters Five Force Analysis
5.1 Bargaining Power of suppliers
5.2 Bargaining power of buyers
5.3 Degree of competition
5.4 Threat of substitution
5.5 Threat of new entrants
6. Market Segmentation
6.1 By Type
6.1.1 primary liver cancer Hepatocellular carcinoma (HCC) Angiosarcoma Cholangiocarcinoma (bile duct cancer) Hepatoblastoma
6.1.2 secondary liver cancer
6.1.3 Benign liver growths
6.2 Diagnosis
6.2.1 ultrasound scans
6.2.2 Confirmatory Needle biopsy
6.2.3 Endoscopic Ultrasound
6.2.4 Laparoscopy
6.2.5 CT Scan
6.2.6 PET Scan
6.2.7 magnetic resonance imaging (MRI) scans
6.3 Therapeutics
6.3.1 Hepatocellular carcinoma
6.3.2 Cholangiocarcinoma
6.3.3 Hepatoblastoma
6.3.4 Targeted therapy
6.3.5 Others
6.4 By End User
6.4.1 Pediatrics
6.4.2 Adults
6.5 By Geography
6.5.1 France
6.5.2 Italy
6.5.3 Germany
6.5.4 Spain
6.5.5 UK
6.5.6 Rest of Europe
7. Competitive Landscape
7.1 Mergers and Acquisitions
7.2 Agreements, Collaborations and Partnerships
7.3 New Product Launches
7.4 Recommendations to new market players
7.5 Value Chain Analysis
8. Company Profiles
8.1 Bayer Schering Pharma AG,
8.2 Onyx Pharmaceuticals, Inc., Celsion Corp.,
8.3 Alnylam Pharmaceuticals, Inc.,
8.4 ArQule, Inc.,
8.5 4SC AG,
8.6 ImClone Systems Inc.,
8.7 Jennerex Biotherapeutics, Inc.,
8.8 Pfizer Inc.,
8.9 F Hoffmann-La Roche Ltd..,
8.10 Bristol-Myers Squibb Company.
9. Appendix
9.1 Abbrevations
9.2 Sources
9.3 Bibliography
9.4 Disclaimer

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
World Cancer Diagnostics Market Future Horizons and Growth Strategies: Supplier Shares by Tumor Marker, Country Segment Forecasts, Competitive Intelligence, Opportunities

World Cancer Diagnostics Market Future Horizons and Growth Strategies: Supplier Shares by Tumor Marker, Country Segment Forecasts, Competitive Intelligence, Opportunities

  • $ 21 100
  • Industry report
  • August 2016
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100. VPGMarketResearch.com's new report is a seven-country strategic analysis of the major business opportunities ...

Cancer Drugs in the FDA Fast Lane: Analytical Tool

Cancer Drugs in the FDA Fast Lane: Analytical Tool

  • $ 10 125
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Download Unlimited Documents from Trusted Public Sources

Therapy Market in Denmark

  • October 2016
    11 pages
  • Therapy  


  • Denmark  

View report >

Opioid Market in the US

  • October 2016
    32 pages
  • Opioid  


    Infectious Dise...  

  • United States  



View report >

Global Vaccine Industry

  • October 2016
    5 pages
  • Vaccine  

    Infectious Dise...  

  • World  



View report >

Therapy Market

10 days ago

Related Market Segments :



Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.